Oxford_Harrington_Centres_in_Oxford_UK_and_Ohio_USA.jpg

The Centre

The Oxford-Harrington Rare Disease Centre is a partnership between the University of Oxford and Harrington Discovery Institute in the US. 

Our Mission

is to deliver new treatments for 400 million people affected by rare diseases worldwide

Our Goal

is to advance 40 drugs into clinical trials in the next 10 years

A Global Partnership

University of Oxford

The University of Oxford ranks number one in the Times Higher Education World University Rankings (2017 to 2023), and its Medical Sciences Division is consistently at the forefront of innovative and lifesaving science. The University has more than 250 principal investigator scientists working on over 350 rare diseases and cutting-edge technologies to accelerate drug development. 

#1
in the world for medicine

Global research in 40
countries

>250
rare disease researchers

>300
spin outs

Harrington Discovery Institute

Harrington Discovery Institute at University Hospitals in Cleveland, Ohio is an international drug discovery and development organisation established to address unmet therapeutic need.

It provides comprehensive support to leading scholars and entrepreneurs across academic centres in the US, UK, and Canada, with a focus on medical breakthroughs that show great promise but would not otherwise advance to clinical trials.

By concentrating philanthropic, scientific and business development resources during the early, high-risk stage of development and creating milestone-driven pathways toward commercialisation, Harrington Discovery Institute de-risks therapeutic candidates in preparation for further investment.

188
medicines in the making

66
institutions supported

15
licenses to pharma

21
medicines in the clinic

39
companies launched